Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

144 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01667133

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia (CML), +16 more
Locations
  • Aichi Cancer Center Hospital Nagoya, Aichi-ken, Japan
  • Akita University Hospital Akita, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima, Japan
  • Kyushu University Hospital Hukuoka-shi, Hukuoka, Japan
View Trial Details
Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

NCT02265731

Conditions
Acute Myeloid Leukemia (AML), Blood Protein Disorders, Cardiovascular Diseases, +30 more
Locations
  • NHO Nagoya Medical Center /ID# 129222 Nagoya, Aichi-ken, Japan
  • Aichi Cancer Center Hospital /ID# 129061 Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital /ID# 129278 Nagoya, Aichi-ken, Japan
  • University of Fukui Hospital /ID# 165801 Yoshida-gun, Fukui, Japan
View all 14 locations
View Trial Details
Completed

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT00750009

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +106 more
Locations
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT01207388

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +23 more
Locations
  • 1102 - LKH Graz Graz, Austria
  • 1107 - Krankenhaus der Elisabethinen Linz, Austria
  • 1106 Salzburg, Austria
  • 1101 - AKH Wien Vienna, Austria
View all 75 locations
View Trial Details

Related conditions